G. Ottaviani and N. Jaffe, The epidemiology of osteosarcoma Pediatric and adolescent osteosarcoma, pp.3-13, 2009.

P. Satalkar, B. S. Elger, and D. M. Shaw, Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?, Science and Engineering Ethics, vol.24, issue.10, pp.1255-1276, 2016.
DOI : 10.1038/nbt1006-1211

Q. He, S. Guo, Z. Qian, and X. Chen, Development of individualized anti-metastasis strategies by engineering nanomedicines, Chemical Society Reviews, vol.6, issue.17, pp.6258-6286, 2015.
DOI : 10.1371/journal.pone.0019662

URL : http://europepmc.org/articles/pmc4540626?pdf=render

A. K. Iyer, G. Khaled, J. Fang, and H. Maeda, Exploiting the enhanced permeability and retention effect for tumor targeting, Drug Discovery Today, vol.11, issue.17-18, pp.812-818, 2006.
DOI : 10.1016/j.drudis.2006.07.005

R. Bazak, M. Houri, S. Achy, S. Kamel, and T. Refaat, Cancer active targeting by nanoparticles: a comprehensive review of literature, Journal of Cancer Research and Clinical Oncology, vol.371, issue.4, pp.141-769, 2015.
DOI : 10.1016/j.jmb.2007.05.011

URL : https://link.springer.com/content/pdf/10.1007%2Fs00432-014-1767-3.pdf

S. P. Chawla, V. S. Chua, L. Fernandez, D. Quon, A. Saralou et al., Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and Osteosarcoma, Molecular Therapy, vol.17, issue.9, pp.17-1651, 2009.
DOI : 10.1038/mt.2009.126

E. Fernandez, A. Imbuluzqueta, M. J. Patino-garcia, and . Blanco-prieto, Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy, Current Pharmaceutical Design, vol.21, issue.42, pp.6104-6124, 2015.
DOI : 10.2174/1381612821666151027152534

G. Huang, L. Yu, L. J. Cooper, M. Hollomon, H. Huls et al., Genetically Modified T cells Targeting Interleukin-11 Receptor ??-Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung Metastases, Cancer Research, vol.72, issue.1, pp.72-271, 2012.
DOI : 10.1158/0008-5472.CAN-11-2778

S. R. Guma, D. A. Lee, L. Yu, N. Gordon, and E. S. Kleinerman, Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis, Pediatric Blood & Cancer, vol.190, issue.8, pp.61-1362, 2014.
DOI : 10.4049/jimmunol.1201314

G. Yang, J. Yuan, and K. Li, EMT transcription factors: implication in osteosarcoma, Medical Oncology, vol.9, issue.4, 2013.
DOI : 10.1158/1541-7786.MCR-11-0093

M. T. Gabriel, L. R. Calleja, A. Chalopin, B. Ory, and D. Heymann, Circulating tumour cells: a review of non-EpCAM-based approaches for cell enrichment and isolation
DOI : 10.1373/clinchem.2015.249706

URL : http://clinchem.aaccjnls.org/content/clinchem/62/4/571.full.pdf

M. Tellez-gabriel, H. K. Brown, R. Young, M. F. Heymann, and D. Heymann, The challenges of detecting circulating tumour cells in sarcoma, Front Oncol, vol.6, issue.202, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01466092

M. Tellez-gabriel, B. Ory, F. Lamoureux, M. F. Heymann, and D. Heymann, Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis, International Journal of Molecular Sciences, vol.6, issue.12, p.17, 2016.
DOI : 10.3389/fonc.2014.00366

URL : https://hal.archives-ouvertes.fr/inserm-01466086

M. F. Heymann, F. Lézot, and D. Heymann, The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma, Cellular Immunology
DOI : 10.1016/j.cellimm.2017.10.011

URL : https://hal.archives-ouvertes.fr/inserm-01644725

M. J. Patiño-garcía and . Blanco-prieto, Lipid nanoparticles enhance the efficacy of chemotherapy in primary and metastatic human osteosarcoma cells, J. Drug Deliv

A. Estella-hermoso-de-mendoza, M. Rayo, F. Mollinedo, and M. J. Blanco-prieto, Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization, European Journal of Pharmaceutics and Biopharmaceutics, vol.68, issue.2, pp.68-207, 2008.
DOI : 10.1016/j.ejpb.2007.06.015

A. Estella-hermoso-de-mendoza, M. A. Campanero, F. Mollinedo, and M. J. Blanco-prieto, Comparative study of A HPLC-MS assay versus an UHPLC-MS/MS for antitumoural alkyl lysophospholipid edelfosine determination in both biological samples and in lipid nanoparticulate systems, J. Chromatogr. Anal. Technol. Biomed. life Sci, vol.23

O. H. Lowry, N. J. Rosenbrough, A. L. Farr, and R. J. Randall, Protein measurement with the Folin phenol reagent, J. Biol. Chem, vol.193, pp.265-275, 1951.

M. F. Heymann, H. K. Brown, and D. Heymann, Drugs in early clinical development for the treatment of osteosarcoma, Expert Opinion on Investigational Drugs, vol.50, issue.6, pp.1265-1280, 2016.
DOI : 10.1038/srep20944

URL : https://hal.archives-ouvertes.fr/inserm-01466096

B. Lasa-saracíbar, M. Á. Aznar, H. Lana, I. Aizpún, A. G. Gil et al., Lipid nanoparticles protect from edelfosine toxicity in vivo, International Journal of Pharmaceutics, vol.474, issue.1-2, pp.474-475, 2014.
DOI : 10.1016/j.ijpharm.2014.07.053

M. Lohmeyer and P. Workman, Growth arrest vs direct cytotoxicity and the importance of molecular structure for the in vitro anti-tumour activity of ether lipids, British Journal of Cancer, vol.72, issue.2, pp.277-286, 1995.
DOI : 10.1038/bjc.1995.325

A. C. Alves, C. Nunes, J. Lima, and S. Reis, Daunorubicin and doxorubicin molecular interplay with 2D membrane models, Colloids and Surfaces B: Biointerfaces, vol.160, pp.610-618, 2017.
DOI : 10.1016/j.colsurfb.2017.09.058

H. L. Neville-webbe, A. Rostami-hodjegan, C. A. Evans, R. E. Coleman, and I. Holen, Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells, International Journal of Cancer, vol.63, issue.3, pp.364-371, 2005.
DOI : 10.1002/ijc.20602

URL : http://onlinelibrary.wiley.com/doi/10.1002/ijc.20602/pdf

P. D. Ottewell, H. K. Brown, M. Jones, T. L. Rogers, S. S. Cross et al., Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice, Breast Cancer Research and Treatment, vol.69, issue.5, pp.133-523, 2012.
DOI : 10.1124/mol.105.020776